The Added Value of Concurrently-Administered Temozolomide Versus Adjuvant Temozolomide Alone in Newly-Diagnosed Glioblastoma

PURPOSE: Temozolomide (TMZ), given concurrently with radiotherapy (RT) and as adjuvant monotherapy afterwards, has led to improved survival in glioblastoma multiforme (GBM). However, it is unclear whether its primary mechanism of action is through enhancement of radiation response or through indepen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sher, David J., Henson, John, Avutu, Bindu, Hochberg, Fred, Batchelor, Tracy, Martuza, Robert, Barker, Fred, Loeffler, Jay S., Chakravarti, Arnab
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2658810/
https://ncbi.nlm.nih.gov/pubmed/18231723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-008-9530-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares